{
    "name": "ferric pyrophosphate IV",
    "comment": "Rx",
    "other_names": [
        "Triferic AVNU"
    ],
    "classes": [
        "Iron Products",
        "Iron Salts"
    ],
    "source": "https://reference.medscape.com/drug/triferic-avnu-ferric-pyrophosphate-4000092",
    "pregnancy": {
        "common": [
            "No data available on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, IV administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes at maternally toxic dose levels that resulted in reductions in the number of live offspring and lower offspring body weights"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of ferric pyrophosphate citrate in human milk, the effects on the breastfed child, or the effect on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Determine iron status on predialysis blood samples; postdialysis serum iron parameters may overestimate serum iron and transferrin saturation"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Serious hypersensitivity reactions, including anaphylactic-type reactions, some life-threatening and fatal, have been reported in patients receiving parenteral iron products",
                        "Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse",
                        "Monitor for signs and symptoms of hypersensitivity during and after HD until clinically stable",
                        "Personnel and therapies should be immediately available to treat, if necessary"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Procedural hypotension",
            "percent": "22"
        },
        {
            "name": "Muscle spasms",
            "percent": "10"
        },
        {
            "name": "Headache",
            "percent": "9"
        },
        {
            "name": "Peripheral edema",
            "percent": "7"
        },
        {
            "name": "Pain in extremity",
            "percent": "7"
        },
        {
            "name": "Dyspnea",
            "percent": "6"
        },
        {
            "name": "Pyrexia",
            "percent": "5"
        },
        {
            "name": "Urinary tract infection",
            "percent": "5"
        },
        {
            "name": "Back pain",
            "percent": "5"
        },
        {
            "name": "Asthenia",
            "percent": "4"
        },
        {
            "name": "Fatigue",
            "percent": "4"
        },
        {
            "name": "Arteriovenous fistula thrombosis",
            "percent": "3"
        },
        {
            "name": "Arteriovenous fistula site hemorrhage",
            "percent": "3"
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": "0.3"
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Intradialytic hypotension",
            "percent": null
        }
    ]
}